Gongwin Biopharm Holdings Co (ROCO:6617) GF Value Rank: 2 (As of Sep. 01, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6617 Gongwin Biopharm Holdings Co Ltd ROCO:6617
57 GF Score
Price NT$120.50
! 5 Warning Signs
View Full Analysis

What is Gongwin Biopharm Holdings Co GF Value Rank?

Gongwin Biopharm Holdings Co ROCO:6617 -1.63% 57 GF Value Rank is 2 as of Sep. 01, 2026, which is at its 10-year median of 2.00. GuruFocus rates ROCO:6617 with a GF Score™ of 57/100. The stock has 5 warning signs investors should review.

Gongwin Biopharm Holdings Co has the GF Value Rank of 2.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Gongwin Biopharm Holdings Co GF Value Rank Related Terms


ROCO:6617 vs VRTX, REGN, MRNA: GF Value Rank Comparison

For the Biotechnology subindustry, Gongwin Biopharm Holdings Co's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gongwin Biopharm Holdings Co GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gongwin Biopharm Holdings Co's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Gongwin Biopharm Holdings Co's GF Value Rank falls into.


ROCO:6617
57GF Score
Gongwin Biopharm Holdings Co Ltd ROCO:6617
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 2 mean?
Gongwin Biopharm Holdings Co (ROCO:6617) has a GF Value Rank of 2 as of Sep. 01, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Gongwin Biopharm Holdings Co and its competitors. This is near median its historical median of 2.00. Over the past decade, Gongwin Biopharm Holdings Co's GF Value Rank has ranged from 2.00 to 9.00.
Is Gongwin Biopharm Holdings Co's GF Value Rank too high?
Gongwin Biopharm Holdings Co's current GF Value Rank of 2 is near median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. Overall, Gongwin Biopharm Holdings Co has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Gongwin Biopharm Holdings Co's GF Value Rank compare to VRTX and REGN?
Gongwin Biopharm Holdings Co's GF Value Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Gongwin Biopharm Holdings Co's own GF Value Rank has ranged from 2.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Gongwin Biopharm Holdings Co and its competitors. Gongwin Biopharm Holdings Co's current GF Value Rank is 2, which is near median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gongwin Biopharm Holdings Co stock overvalued right now?
Gongwin Biopharm Holdings Co (ROCO:6617) has a current GF Value Rank of 2. The current GF Value Rank is 2, which is near median its 10-year median of 2.00. Gongwin Biopharm Holdings Co's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Gongwin Biopharm Holdings Co (ROCO:6617), the current GF Value Rank is 2 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gongwin Biopharm Holdings Co Business Description

Address 3rd Floor, No.80, Jianguo North Road, Section 1, Zongshan District, Taipei, TWN, 10491
Gongwin Biopharm Holdings Co Ltd is a Taiwan-based biopharmaceutical company focused on developing novel anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma. The Group includes pharmaceutical research and development, drug testing, pharmaceutical technology consulting, biotechnology services, technology transfer, and the sale of new drugs.
57GF Score

Get the complete analysis for ROCO:6617

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$120.50
Price